Vanquabio
Chicago, US · Founded 2019 · 36 employees on LinkedIn · 3 known investors
Find your way into Vanquabio
466 people in our graph share verified history with the Vanquabio team — schools, employers, funds. One of them is your warm intro.
Liz Westhouseunlockedknows Jim Sullivan, Ph.D. · together at Northwestern University (overlapped)
×3knows the team · via AbbVie
×2knows the team · via Northwestern University
×6knows the team · via Trinity College Dublin
Vanqua Bio is a biotechnology company developing molecules intended to become medicines for neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and related neurological conditions. It serves patients with these diseases through its drug discovery and development work.
Founders & leadership
JS
Jim SullivaninCEOJim Sullivan is an experienced R&D executive in the pharmaceutical and biotechnology industries who has advanced over 100 compounds into clinical development across multiple disease areas and technology platforms, including recent product launches for hepatitis C and cancer. He brings board-level experience in company building.
KH
Kevin HuntinCSOKevin Hunt has spent eight years working on drug discovery and development at Genuiti, Vanqua, and Edgewise, focusing on neurodegenerative diseases, rare pediatric disorders, and cardiometabolic conditions. He serves as Chief Scientific Officer at Vanqua Bio.
Investors · 3
Frequently asked questions
- What does Vanquabio do?
- Vanqua Bio is a biotechnology company developing molecules intended to become medicines for neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and related neurological conditions. It serves patients with these diseases through its drug discovery and development work.
- Who are Vanquabio's investors?
- Vanquabio's investors include Avoro Capital Advisors, OrbiMed, Pontifax Venture Capital.
- Where is Vanquabio headquartered?
- Vanquabio is headquartered in Chicago, US.